2. Signaling Pathways
  3. Apoptosis
  4. IAP
  5. cIAP-2 Isoform

cIAP-2

cIAP-2 (cellular inhibitor of apoptosis protein 2, encoded by BIRC3) is a member of the inhibitor of apoptosis protein (IAP) family that functions as a signaling regulator linking cell survival, inflammatory responses, and programmed cell death pathways[1][2]. Mechanistically, cIAP-2 acts as an E3 ubiquitin ligase within TNF receptor and pattern-recognition receptor signaling complexes, where it contributes to ubiquitination-dependent activation of NF-κB signaling and downstream transcriptional programs that support cellular adaptation to stress and immune stimulation[3][4]. Through cooperation with TRAF family proteins, cIAP-2 participates in the regulation of receptor-mediated signaling networks that control apoptosis, innate immunity, and inflammatory responses[3][5]. In disease settings, altered BIRC3 expression or mutation has been associated with hematologic malignancies and other cancers, highlighting the importance of cIAP-2 in tumor cell survival and therapy response[6][7]. Compared with the closely related isoform cIAP-1 (BIRC2), cIAP-2 displays distinct expression kinetics and regulatory patterns; cIAP-2 is strongly inducible by inflammatory cytokines through NF-κB-dependent mechanisms, whereas cIAP-1 is more constitutively expressed and is thought to support rapid signaling events[8]. This distinction suggests that cIAP-2 may contribute preferentially to sustained or later-phase signaling responses following inflammatory stimulation[8]. For experimental applications, cIAP-2 is widely investigated as a target of SMAC mimetics and other IAP-directed compounds that promote cIAP degradation or disrupt cIAP-associated signaling complexes, providing useful tools for studying NF-κB regulation, apoptosis sensitivity, and anticancer therapeutic mechanisms[2][9].

References:

cIAP-2 Related Products (13):

Cat. No. Product Name Effect Purity
  • HY-15989
    SM-164
    		Antagonist 99.53%
    SM-164 is a cell-permeable Smac mimetic compound. SM-164 binds to XIAP protein containing both the BIR2 and BIR3 domains with an IC50 value of 1.39 nM and functions as an extremely potent antagonist of XIAP.
  • HY-12600
    AZD5582
    		Antagonist 99.61%
    AZD5582 is an antagonist of the inhibitor of apoptosis proteins (IAPs), which binds to the BIR3 domains cIAP1, cIAP2, and XIAP with IC50s of 15, 21, and 15 nM, respectively. AZD5582 induces apoptosis.
  • HY-15454
    Xevinapant
    		Antagonist 99.91%
    Xevinapant (AT-406) is a potent and orally bioavailable Smac mimetic and an antagonist of IAPs, and it binds to XIAP, cIAP1, and cIAP2 proteins with Ki of 66.4, 1.9, and 5.1 nM, respectively.
  • HY-15989A
    SM-164 hydrochloride
    		Antagonist
    SM-164 hydrochloride is a cell-permeable Smac mimetic compound. SM-164 binds to XIAP protein containing both the BIR2 and BIR3 domains with an IC50 value of 1.39 nM and functions as an extremely potent antagonist of XIAP.
  • HY-N0732
    Jolkinolide B
    		Inhibitor 99.65%
    Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis.
  • HY-12440
    HM90822
    		Antagonist
    HM90822 is an orally active IAP antagonist. HM90822 induces ubiquitination and proteasome-dependent degradation of XIAP, cIAP1 and cIAP2 in sensitive pancreatic cancer cells. HM90822 induces Apoptotic cell death. HM90822 inhibits tumor growth in Panc-1 pancreatic cancer xenograft and orthotopic mouse models. HM90822 can be used for the research of pancreatic cancer.
  • HY-175445
    GNE-5472
    		Antagonist
    GNE-5472 is a potent bifunctional ERα PRRTAC degrader, with its E3 ligand being a pan-IAP antagonist. GNE-5472 antagonizes cIAP1/2, activating the non-classical NF-κB pathway, resulting in a significant upregulation of TNFα expression. GNE-5472 inhibits the proliferation of breast cancer cells and induces cell apoptosis. GNE-5472 can be used for the study of breast cancer.
  • HY-13208
    Xevinapant hydrochloride
    		Antagonist 98.11%
    Xevinapant (AT-406) hydrochloride is a potent and orally bioavailable Smac mimetic and an antagonist of the inhibitor of apoptosis proteins (IAPs). Xevinapant hydrochloride binds to XIAP, cIAP1, and cIAP2 proteins with Kis of 66.4, 1.9, and 5.1 nM, respectively. Xevinapant hydrochloride effectively antagonizes XIAP BIR3 protein in a cell-free functional assay, induces rapid degradation of cellular cIAP1 protein, and inhibits cancer cell growth in various human cancer cell lines. Xevinapant hydrochloride is highly effective in induction of apoptosis in xenograft tumors.
  • HY-110346
    AZD5582 dihydrochloride
    		Antagonist 99.92%
    AZD5582 dihydrochloride is an antagonist of the inhibitor of apoptosis proteins (IAPs), which binds to the BIR3 domains cIAP1, cIAP2, and XIAP with IC50s of 15, 21, and 15 nM, respectively. AZD5582 induces apoptosis.
  • HY-151966
    TD1092
    		Degrader 99.49%
    TD1092 is a pan-IAP degrader, degrades cIAP1, cIAP2, and XIAP. TD1092 activates Caspase 3/7, and promotes cancer cells apoptosis via IAP degradation. TD1092 inhibits TNFα mediated NF-κB pathway and reduces the phosphorylation of IKK, IkBα, p65, and p38. TD1092 can act as PROTAC, and is used for cancer research.
  • HY-111886
    KHS108-MV1
    		Antagonist
    KHS108-MV1 is a conjugate of KHS108 and MV1. KHS108 is a ligand for TACC3. MV1 is an IAP antagonist that binds to cIAP1, cIAP2, and XIAP. KHS108-MV1 can be used in the research of breast cancer and fibrosarcoma.
  • HY-155294
    SM-122
    		Degrader
    SM-122 is a monovalent Smac mimetic targeting cellular inhibitor of apoptosis protein (cIAP)-1/2. SM-122 can induce cIAP-1/2 degradation and weakly induce apoptosis in tumor cells. SM-122 can be used for the research of cancer, such as breast cancer.
  • HY-N0732R
    Jolkinolide B (Standard)
    		Inhibitor
    Jolkinolide B (Standard) is the analytical standard of Jolkinolide B (HY-N0732). This product is intended for research and analytical applications. Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis.
Cat. No. Product Name / Synonyms Application Reactivity